Assessment of SARS-CoV-2 Infection Prevalence in Homeless Shelters — Four U.S. Cities, March 27–April 15, 2020Emily Mosites, Julie Stoltey, Madeline Sankaran et al.|MMWR Morbidity and Mortality Weekly Report|2020Cited by 240
Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for DeliverySpyros A. Kalams, Scott Parker, Marnie Elizaga et al.|The Journal of Infectious Diseases|2013Cited by 197
Durable HIV-1 antibody and T-cell responses elicited by an adjuvanted multi-protein recombinant vaccine in uninfected human volunteersPaul Goepfert, Thomas G. Evans, Georgia D. Tomaras et al.|Vaccine|2006Cited by 93
High‐Dose Recombinant Canarypox Vaccine Expressing HIV‐1 Protein, in Seronegative Human SubjectsPaul Goepfert, Helen Horton, M. Juliana McElrath et al.|The Journal of Infectious Diseases|2005Cited by 65